It’s been another low volume period, the type of week that can be frustrating but ultimately rewarding for the buyers. Apparently the good folk at Peloton can’t believe they’re getting shares at these prices, particularly as IHL is getting close to such a significant period of news flow.
The same contact mentioned to me today that GW Pharmaceuticals has a similar strategy to the one IHL is targeting. They have IP in a cannabis drug called Epidiolex. Apparently GW Pharma now has a $3 billion market cap.